医疗保健
业务
透视图(图形)
面子(社会学概念)
公共关系
公共经济学
经济增长
政治学
经济
计算机科学
社会科学
社会学
人工智能
作者
Denis Horgan,Marcel Tanner,Charu Aggarwal,David M. Thomas,Surbhi Grover,Lina Basel‐Salmon,Rodrigo Dienstmann,Tira J. Tan,Woong‐Yang Park,Hadi Mohamad Abu Rasheed,Lillian L. Siu,Brigette Ma,Rocío Ortiz‐López,Marc Van den Bulcke,Silvia Castillo Taucher,Andrea Ferris,Naureen Starling,Umberto Malapelle,John Longshore,Hugo A. Barrera‐Saldaña
出处
期刊:JCO global oncology
[American Society of Clinical Oncology]
日期:2025-01-01
卷期号:11 (11): e2400416-e2400416
被引量:11
摘要
Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors—scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy–related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.
科研通智能强力驱动
Strongly Powered by AbleSci AI